Health ❯ Healthcare

Obesity

Treatment Options Weight Management Weight Loss Weight Loss Treatments Treatment Obesity Treatment Medications Weight Loss Drugs Obesity Management Health Risks

Waist Size Outperforms BMI at Predicting Heart Risk

New JACC pooled analysis shows simple waist measurements reclassify cardiovascular risk prompting calls for routine clinical use.

UK Regulator Approves Eli Lilly’s Foundayo Tablet for Weight Loss and Type 2 Diabetes

Retailers Move to Fill $50 Medicare GLP‑1 Prescriptions

Eli Lilly Opens Limited Early Access to Experimental Obesity Drug Retatrutide

New Studies and Policy Pilots Push GLP‑1 Drugs into Wider Use as Cost and Safety Questions Grow

Wegovy Pill Hits UK Private Market as Safety and Access Worries Rise

GLP‑1 Use Reaches 11% of U.S. Adults as New Evidence Spurs Policy and Safety Scrutiny

Wegovy Pill Approved, Private Sales Start in UK

Superdrug Begins UK Sales of Wegovy Oral Weight‑Loss Tablets

Medicare Launches GLP‑1 Bridge to Offer Select Weight‑Loss Drugs for $50 a Month

Older Adults With Obesity Now Match Peers’ Blood Pressure and Cholesterol

Medicare Launches 18‑Month GLP‑1 Bridge to Cover Weight‑Loss Drugs

Brazil Launches Two-Year Semaglutide Pilot for 250 SUS Patients

GLP‑1 Drugs Appear to Raise Testosterone and Improve Sperm Measures in Obese Men

New Studies Find Less Movement and Behavioral Signals in GLP‑1 Weight‑loss Users

Rutgers Study Finds Current GLP‑1 Use Linked to Weaker Paths From Impulse and Alcohol to Violence

MHRA Approves Wegovy Weight‑Loss Tablet as Private Demand Soars

Severe GLP‑1 Overdoses Rise as Online Access and Compounded Vials Expand

New Data Show Lower Activity, Muscle Loss and Mood Changes Linked to GLP‑1 Weight Drugs

Early Evidence Suggests GLP‑1 Weight Drugs Can Raise Testosterone and Improve Sperm in Men With Obesity